Literature DB >> 9108442

Effects of chronic administration of tamoxifen and toremifene on DNA adducts in rat liver, kidney, and uterus.

D Li1, Y Dragan, V C Jordan, M Wang, H C Pitot.   

Abstract

To assess the effects of chronic administration of tamoxifen (TAM) and toremifene (TOR) on genetic damage related to carcinogenesis, we measured DNA adduct formation by (32)P-postlabeling in liver, kidney, and uterus of Fischer rats given TAM or TOR in the diet for 18 months. TAM induced high levels of DNA adducts in the liver in a dose-dependent manner. The total adduct levels were 3000 +/- 870 and 6100 +/- 1500 adducts per 10(9) nucleotides for the 250- and 500-ppm groups, respectively. TOR induced a dose-dependent level of adducts that was lower than that observed for TAM. The total hepatic adduct level was 70 +/- 5, 130 +/- 20, and 70 +/- 20 for 250, 500, and 750 ppm TOR, respectively. Both TAM and TOR induced a low level of adducts in the kidney, and TOR significantly enhanced endogenous DNA adduct formation. The total adduct level was 480 +/- 140, 420 +/- 210, and 680 +/- 80 adducts per 10(9) nucleotides for control, 500 ppm TAM, and 500 ppm TOR, respectively. Although neither TAM nor TOR induced adducts in the uterus, TAM significantly enhanced endogenous DNA modifications in this tissue. The total uterine adduct level was 70 +/- 30, 130 +/- 50, and 70 +/- 20 for control, 500 ppm TAM, and 500 ppm TOR, respectively. These observations demonstrate a correlation between DNA adduct formation and carcinogenicity for these compounds. The effectiveness of TOR and TAM in increasing endogenous DNA adducts indicates that a mechanism other than direct DNA damage may also be involved in their carcinogenicity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9108442

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Gynaecological effects of tamoxifen.

Authors:  S M Ismail
Journal:  J Clin Pathol       Date:  1999-02       Impact factor: 3.411

Review 2.  Antiestrogens--tamoxifen, SERMs and beyond.

Authors:  K Dhingra
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

Review 3.  Clinical pharmacology of selective estrogen receptor modulators.

Authors:  B Haynes; M Dowsett
Journal:  Drugs Aging       Date:  1999-05       Impact factor: 3.923

4.  Polysaccharide Peptide Extract From Coriolus versicolor Increased Tmax of Tamoxifen and Maintained Biochemical Serum Parameters, With No Change in the Metabolism of Tamoxifen in the Rat.

Authors:  Valentina Razmovski-Naumovski; Benjamin Kimble; Daunia Laurenti; Srinivas Nammi; Hisayoshi Norimoto; Kelvin Chan
Journal:  Front Pharmacol       Date:  2022-04-01       Impact factor: 5.988

5.  Microsomal epoxide hydrolase of rat liver is a subunit of theanti-oestrogen-binding site.

Authors:  F Mésange; M Sebbar; B Kedjouar; J Capdevielle; J C Guillemot; P Ferrara; F Bayard; F Delarue; J C Faye; M Poirot
Journal:  Biochem J       Date:  1998-08-15       Impact factor: 3.857

6.  Influence of gender on tamoxifen-induced biochemical changes in serum of rats.

Authors:  Faried Abdel-Kader El-Sayed Hemieda
Journal:  Mol Cell Biochem       Date:  2007-02-06       Impact factor: 3.842

7.  Differences in the timing and magnitude of Pkd1 gene deletion determine the severity of polycystic kidney disease in an orthologous mouse model of ADPKD.

Authors:  Kelly A Rogers; Sarah E Moreno; Laurie A Smith; Hervé Husson; Nikolay O Bukanov; Steven R Ledbetter; Yeva Budman; Yuefeng Lu; Bing Wang; Oxana Ibraghimov-Beskrovnaya; Thomas A Natoli
Journal:  Physiol Rep       Date:  2016-06

Review 8.  Transgenic rat models for mutagenesis and carcinogenesis.

Authors:  Takehiko Nohmi; Kenichi Masumura; Naomi Toyoda-Hokaiwado
Journal:  Genes Environ       Date:  2017-02-01

Review 9.  Selective estrogen receptor modulators: tissue specificity and clinical utility.

Authors:  Stephen Martinkovich; Darshan Shah; Sonia Lobo Planey; John A Arnott
Journal:  Clin Interv Aging       Date:  2014-08-28       Impact factor: 4.458

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.